Retinal vascular diameter not affected by cataract surgery and changes to blood pressure

Article

Cataract surgery and changes to blood pressure caused by sodium restriction has been shown to have no effect on retinal vascular diameter.

Cataract surgery and changes to blood pressure caused by sodium restriction has been shown to have no effect on retinal vascular diameter in a recent study published in Clinical Ophthalmology.

The study by Takatoshi Tano et al., from Jutendo University School of Medicine and the National Institute of Public Health, Tokyo, Japan, investigated the effect of cataract surgery and blood pressure fluctuations induced by one week of sodium restriction on retinal vascular diameter.

For one week 100 patients were restricted of sodium and 100 patients were not restricted of sodium. The diameter of the retinal vessels and blood pressure were compared between both groups; diameter being measured using an objective computer-based method.

The results demonstrated that after cataract surgery neither group experienced a change in diameter of retinal vessels. However, a notable reduction in blood pressure was seen in the sodium restriction group. Through multiple linear regression analyses performed by the researchers it was found that an increase in retinal arteriolar diameter was associated with diabetes, hyperlipidaemia and alcohol.

From the results it was concluded that cataract surgery and reduction in blood pressure caused by sodium restriction have no significant effect on retinal arteriolar diameter.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.